Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

Members of Congress Agree: Reg A+ Rules Need National Standard

Biotech IPOs Infographic

We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

What to Watch: Vaccines – Calling the Shots

vaccines-calling-shots-vi

Recently, PBS’s NOVA had an episode on the reemergence of diseases (including measles, whooping cough, and mumps) that had previously been largely eradicated in the US by vaccines, in part because nervous parents are skipping their children’s shots. At least ten percent of parents delay or skip some recommended vaccines, and one percent don’t vaccinate at all. What’s driving people away, and what are the consequences? Those are the questions explored in Vaccines — Calling Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

FierceBiotech Names 2014 Fierce 15

FierceBiotech

FierceBiotech released their much-anticipated 2014 Fierce 15 list today, their annual list of private biotech upstarts to watch. We’ll be hearing from three of them at next month’s BIO Investor Forum, October 7-8 in San Francisco: Adaptimmune and Sutro Biopharma will be making company presentations, and Editas Medicine CEO Katrine Bosley will participate as a panelist in one of our therapeutic workshops, Gene Therapy Ascending? Today’s Advancements Over Past Hurdles. Here’s the scoop on each, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Jim Greenwood: Biopharma Answers the Call for Cures

jim-gw

Recently, BIO President and CEO Jim Greenwood participated in a roundtable hosted by Congressman Joe Pitts (PA-16) to discuss new ways to expedite new cures for patients in need. C-SPAN covered the event, which may be viewed below:    Yesterday The Hill published an op-ed by Jim which spells out in more detail one of BIO’s proposals to accelerate new cures and treatments: I propose the development and execution of a large-scale, longitudinal study to Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Participating in IDSA Stakeholder Group on Antimicrobial Resistance

MRSA

BIO will be participating in a newly formed partnership which will work collaboratively to inform federal policy and find ways to better combat the growing crisis of antimicrobial resistance. Launched yesterday by the Infectious Diseases Society of America (IDSA), which also released foundation principles for the group, the U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR) will hold its inaugural meeting in Philadelphia next month on October 9th. BIO joins more than 75 other national organizations Read More >

Health, Public Policy  |  1 Comment  |  Email This Post
Tags: , , , ,